前列腺癌激素治疗

预约门诊
打印

妙佑医疗国际的方法

The top-ranked doctors at Mayo Clinic provide expert care for those with prostate cancer. At Mayo Clinic, you can expect:

  • Advanced treatment options. At Mayo Clinic, specialists have access to the latest treatment innovations, including clinical trials, even after hormone therapy stops working.
  • Collaboration. At Mayo Clinic, oncologists, urologists, radiation oncologists, pathologists and radiologists work as a multidisciplinary team to provide comprehensive care for people with prostate cancer.
  • Experienced care teams. Each year, thousands of people with prostate cancer receive care at Mayo Clinic. This experience means your care team is prepared with knowledge and resources to provide you with exactly the care you need. Mayo specialists are deeply experienced not just in one specific aspect of the disease but across all the specialties involved in prostate cancer care.
  • Nationally recognized expertise. Mayo Clinic Comprehensive Cancer Center meets the strict standards for a National Cancer Institute-designated comprehensive cancer center. These standards recognize scientific excellence and a multispecialty approach focused on cancer prevention, diagnosis and treatment. Mayo Clinic Comprehensive Cancer Center is the only National Cancer Institute-designated comprehensive cancer center with three locations, in Arizona, Florida and Minnesota.

专长与排名

自 1990 年开始发布排名以来，妙佑医疗国际一直被《美国新闻与世界报道》评为最佳癌症医院之一。最近，在《美国新闻与世界报道》2024-2025 年度全美最佳癌症医院评选中，妙佑医疗国际明尼苏达州罗切斯特院区、妙佑医疗国际佛罗里达州杰克逊维尔院区和妙佑医疗国际亚利桑那州凤凰城/斯科茨代尔院区均被评为最佳癌症医院之一。

妙佑医疗国际亚利桑那州院区

妙佑医疗国际佛罗里达州院区

妙佑医疗国际明尼苏达州院区

妙佑区域医疗系统

伦敦妙佑医疗中心

有关账单与保险的更多信息：

‏‏妙佑医疗国际设于亚利桑那州、佛罗里达州以及明尼苏达州的院区

妙佑区域医疗系统

来自妙佑医疗国际员工
申请预约
医生与科室
July 15, 2025
打印
  1. Prostate cancer. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459. Accessed May 27, 2025.
  2. Prostate cancer: Early stage. National Comprehensive Cancer Network. https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients/guidelines-for-patients-details?patientGuidelineId=49. Accessed May 27, 2025.
  3. Lowrance W, et al. Updates to advanced prostate cancer: AUA/SUO guideline (2023). The Journal of Urology. 2023; doi:10.1097/JU.0000000000003452.
  4. Hormone therapy for prostate cancer. National Cancer Institute. https://www.cancer.gov/types/prostate/prostate-hormone-therapy-fact-sheet. Accessed May 27, 2025.
  5. Smith MR. Side effects of androgen deprivation therapy. https://www.uptodate.com/contents/search. Accessed Feb. 16, 2023.
  6. Dmochowski RR, et al., eds. Management of recurrent and newly metastatic prostate cancer. In: Campbell-Walsh-Wein Urology. 13th ed. Elsevier; 2026. https://www.clinicalkey.com. Accessed May 27, 2025.
  7. Hussain M, et al. Metastatic hormone-sensitive prostate cancer and combination treatment outcomes: A review. JAMA Oncology. 2024; doi:10.1001/jamaoncol.2024.0591.
  8. Hamid AA, et al. Metastatic hormone-sensitive prostate cancer: Toward an era of adaptive and personalized treatment. American Society of Clinical Oncology Educational Book. 2023; doi:10.1200/EDBK_390166.
  9. Gudenkauf LM, et al. Balancing hormone therapy: Mitigating adverse effects of androgen-deprivation therapy and exploring alternatives in prostate cancer management. American Society of Clinical Oncology Educational Book. 2024; doi:10.1200/EDBK_433126.
  10. Boue A, et al. Does hormone therapy impact cognition in patients with prostate cancer? A systematic review and meta-analysis. Cancer. 2024; doi:10.1002/cncr.35210.
  11. Solanki AJ, et al. A practical guide for assessing and managing cardiovascular risk during androgen-deprivation therapy in patients with prostate cancer. Cancer. 2024; doi:10.1002/cncr.35285.
  12. Lupron (prescribing information). AbbVie Inc.; 2023. https://www.lupron.com/pi.html. Accessed June 6, 2025.
  13. Zoladex (prescribing information). AstraZeneca Pharmaceuticals LP; 2023. https://www.zoladexhcp.com/dosing-administration/. Accessed June 6, 2025.
  14. Vaz R, et al. Testicular cancer — Surgical treatment. Frontiers in Endocrinology. 2019; doi:10.3389/fendo.2019.00308.
  15. Dawson NA, et al. Overview of the treatment of castration-resistant prostate cancer (CRPC). https://www.uptodate.com/contents/search. Accessed June 12, 2025.
  16. Hormone therapy for prostate cancer. National Cancer Institute. https://www.cancer.gov/types/prostate/prostate-hormone-therapy-fact-sheet. Accessed June 12, 2025.
  17. Harris WP, et al. Androgen deprivation therapy: Progress in understanding mechanisms of resistance and optimizing androgen depletion. Nature Clinical Practice Urology; 2009. doi:10.1038/ncpuro1296.
  18. Cancer stat facts: Prostate cancer. National Cancer Institute. https://seer.cancer.gov/statfacts/html/prost.html. Accessed June 12, 2025.
  19. Harris KM. Allscripts EPSi. Mayo Clinic. April 23, 2024.
  20. Questions to ask about prostate cancer. American Cancer Society. https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/talking-with-doctor.html. Accessed June 18, 2025.
  21. Questions to ask about cancer care. National Comprehensive Cancer Network. https://www.nccn.org/patientresources/patient-resources/resources-for-patients-caregivers/questions-to-ask-about-cancer. Accessed June 18, 2025.
  22. Anheuser P, et al. Complications associated with inguinal orchiectomy and scrotal orchiectomy. Urologe. 2014; doi:10.1007/s00120-014-3487-3.
  23. Hormone therapy for advanced prostate cancer. Mayo Clinic Press. https://mcpress.mayoclinic.org/cancer/hormone-therapy-for-advanced-prostate-cancer. Accessed June 18, 2025.

相关

Mayo Clinic 新闻

产品与服务

前列腺癌激素治疗